LOGIN  |  REGISTER
Cue Biopharma

Astellas Pharma (OTCMKTS: ALPMY) Stock Quote

Last Trade: US$10.46 0.17 1.65
Volume: 4,202
5-Day Change: -1.00%
YTD Change: -1.00%
Market Cap: US$18.720B

Latest News From Astellas Pharma

HealthStocksHub
SHANGHAI and SUZHOU, China and TOKYO , Dec. 28, 2023 /PRNewswire/ -- Elpiscience Biopharma, Ltd. (Chairman and CEO: Darren Ji , MD, Ph.D., "Elpiscience") and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced a research collaboration and license agreement for novel bi-specific... Read More
TOKYO , Dec. 21, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") announced today that it has completed the acquisition of Propella Therapeutics, Inc. (President and CEO: William Moore , "Propella"), and has become a wholly owned subsidiary of Astellas as of U.S. Eastern Time December 21, 2023 . Through the acquisition of Propella, Astellas has acquired PRL-02 (abiraterone... Read More
PADCEV plus pembrolizumab approved based on groundbreaking EV-302 trial Confirmatory trial found PADCEV plus pembrolizumab nearly doubled median overall survival compared to standard of care platinum-based chemotherapy TOKYO and NEW YORK , Dec. 15, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that on December 15 , 2023 the U.S.... Read More
TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has successfully completed the acquisition of IVERIC bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio , "Iveric Bio") with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. (the "Acquisition"). The... Read More
Clinical data submitted are consistent with global data and support enfortumab vedotin as a platinum-free option in patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy TOKYO and BOTHELL, Wash. , March 9, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc.... Read More
Astria Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB